News & Updates

Show Multimedia Only
Esketamine outperforms quetiapine in head-to-head depression trial

Esketamine outperforms quetiapine in head-to-head depression trial

30 Oct 2023 byJairia Dela Cruz

In patients with treatment-resistant depression, esketamine nasal spray appears to have superior efficacy compared with extended-release quetiapine when used in combination with conventional antidepressants.

30 Oct 2023
Canagliflozin holds promise against MAFLD in T2D patients

Canagliflozin holds promise against MAFLD in T2D patients

27 Oct 2023 byStephen Padilla

Patients with type 2 diabetes (T2D) who received canagliflozin benefit from improved liver biochemistry and metabolism, a recent study has shown. In addition, treatment with canagliflozin appears to confer positive effects on liver fibrosis.

27 Oct 2023